The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

May 1, 2009 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Safety Warnings and Label Changes

A possible market withdrawal may be imminent for propoxyphene-containing products. In December 2008, the American Society of Health-Systems Pharmacists (ASHP) sent a petition to the Food and Drug Administration (FDA) asking for the removal of propoxyphene-containing products from the US market due to poor effectiveness and safety profiles.1 On March 2, 2009, the ASHP reported a close vote of 14 to 12 in favor of the removal of propoxyphene-containing products from the US market based on testimony from a joint meeting of the FDA’s Drug Safety and Risk Management and Anesthetic and Life Support Drugs Advisory Committees on January 30.2 Issues included are its relationship to drug-related deaths, limited analgesic usefulness, and unfavorable risk-to-benefit ratio. At press time, a final decision had not been made.

You Might Also Like
  • Drug Updates
  • Drug Updates
  • Drug Updates: Lorcaserin, Acetaminophen, and More
Explore This Issue
May 2009
Also By This Author
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients

Wearing medicated transdermal patches while undergoing magnetic resonance imaging (MRI) scans can cause skin burns on the direct patch area.3 Some transdermal patches contain metallic backing or other layers that can overheat during an MRI scan. Patches have many indications including anti-emetics (e.g., granisetron), antidepressants (e.g., selegiline), hormone replacement (e.g., estrogen, testosterone), analgesia (e.g., fentanyl), and smoking cessation (e.g., nicotine). The FDA is evaluating patch contents and labeling to ensure that patients receive this warning about burns. Until the FDA makes a final decision, healthcare providers are asked to warn patients wearing a medicated patch to remove and dispose of it prior to undergoing an MRI. After the scan, the patch should be replaced. When filling out the health history questionnaire at the time of an MRI, patients should include information about medicated transdermal patches.4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

New Approvals

  • Febuxostat (Uloric) was FDA approved for treating hyperuricemia in gout patients.12 Febuxostat is a potent, non-purine, selective, xanthine oxidase inhibitor, structurally different from other xanthine oxidase inhibitors. Availability will be in 40- and 80-mg tablets (once-daily dosing). It is not recommended for patients with asymptomatic hyperuricemia, and does not require dosage adjustment for patients with mild to moderate hepatic or renal impairment.
  • Hylan G-F 20 (Synvisc-One) has been FDA approved as a single, intra-articular injection viscosupplement for treating knee osteoarthritis.13
  • Morphine sulfate extended-release capsules (Avinza) are now also available in 45- and 75-mg dosage strengths. This is in addition to the 30-, 60-, 90-, and 120-mg capsules already available. Avinza is FDA approved for treating moderate to severe chronic pain in patients needing around-the-clock analgesia.14
  • Topical coal tar foam 2% (Scytera) has been FDA approved for treating chronic psoriasis. It contains an odor neutralizer and spreads easily.15

Genentech is voluntarily withdrawing efalizumab (Raptiva), a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML).5 The phased withdrawal will run through June 8, 2009, at which time the drug will no longer be available in the United States. Physicians are being asked not to start any new patients on efalizumab and to discuss alternate therapies with their patients currently taking efalizumab.

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates Issue: May 2009

You Might Also Like:
  • Drug Updates
  • Drug Updates
  • Drug Updates: Lorcaserin, Acetaminophen, and More
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)